Actavis would pay more than $210 a share for Allergan, people briefed on the matter said, possibly thwarting a monthslong hostile bid by Valeant Pharmaceuticals and William A. Ackman.
By MICHAEL J. DE LA MERCED, New York Times
Sun, 11/16/2014 - 2:38pm
Actavis would pay more than $210 a share for Allergan, people briefed on the matter said, possibly thwarting a monthslong hostile bid by Valeant Pharmaceuticals and William A. Ackman.